DNA mismatch repair-deficient colorectal cancers (CRCs) accumulate quite a few frameshift mutations at repetitive sequences acknowledged as microsatellite instability (MSI). When coding mononucleotide repeats (cMNRs) are affected, tumors accumulate frameshift mutations and untimely termination codons (PTC) doubtlessly resulting in truncated proteins.
Nonsense-mediated RNA decay (NMD) can degrade PTC-containing transcripts and defend from such defective proteins. Because it additionally regulates regular transcripts and mobile physiology, we examined whether or not NMD genes themselves are targets of MSI frameshift mutations.
A excessive frequency of cMNR frameshift mutations within the UPF3A gene was present in MSI CRC cell traces (67.7%), MSI colorectal adenomas (55%) and carcinomas (63%). In regular colonic crypts, UPF3A expression was restricted to single chromogranin A-positive cells. SILAC-based proteomic evaluation of KM12 CRC cells revealed UPF3A-dependent down-regulation of a number of enzymes concerned in ldl cholesterol biosynthesis.
Moreover, reconstituted UPF3A expression brought about alterations of 85 phosphosites in 52 phosphoproteins. Most of them (38/52, 73%) reside in nuclear phosphoproteins concerned in regulation of gene expression and RNA splicing. Since UPF3A mutations can modulate the (phospho)proteomic signature and expression of enzymes concerned in ldl cholesterol metabolism in CRC cells, UPF3A might affect different processes than NMD and lack of UPF3A expression would possibly present a progress benefit to MSI CRC cells.
Proximity labeling proteomics reveals important regulators for interior nuclear membrane protein degradation in crops
The interior nuclear membrane (INM) selectively accumulates proteins which can be important for nuclear features; nevertheless, overaccumulation of INM proteins leads to a spread of uncommon genetic problems. To date, little is understood about how faulty, mislocalized, or abnormally amassed membrane proteins are actively faraway from the INM, particularly in crops and animals.
Right here, through evaluation of a proximity-labeling proteomic profile of INM-associated proteins in Arabidopsis, we establish important elements for an INM protein degradation pathway. We present that this pathway depends on the CDC48 complicated for INM protein extraction and 26S proteasome for subsequent protein degradation.
Furthermore, we present that CDC48 on the INM could also be regulated by a subgroup of PUX proteins, which decide the substrate specificity or have an effect on the ATPase exercise of CDC48. These PUX proteins particularly affiliate with the nucleoskeleton beneath the INM and bodily work together with CDC48 proteins to negatively regulate INM protein degradation in crops.
TMT-based Quantitative Proteomics Evaluation Reveals the Attenuated Replication Mechanism of Newcastle Illness Virus Attributable to Nuclear Localization Sign Mutation in Viral Matrix Protein
Nuclear localization of cytoplasmic RNA virus proteins mediated by intrinsic nuclear localization sign (NLS) performs important roles in profitable virus replication. We beforehand reported that NLS mutation within the matrix (M) protein clearly attenuates the replication and pathogenicity of Newcastle illness virus (NDV), however the attenuated replication mechanism stays unclear.
On this research, we confirmed that M/NLS mutation not solely disrupted M’s nucleocytoplasmic trafficking attribute but in addition impaired viral RNA synthesis and transcription. Utilizing TMT-based quantitative proteomics evaluation of BSR-T7/5 cells contaminated with the parental NDV rSS1GFP and the mutant NDV rSS1GFP-M/NLSm harboring M/NLS mutation, we discovered that rSS1GFP an infection stimulated a lot larger portions and extra expression modifications of differentially expressed proteins concerned in host cell transcription, ribosomal construction, posttranslational modification, and intracellular trafficking than rSS1GFP-M/NLSm an infection.
Additional in-depth evaluation revealed that the dominant nuclear accumulation of M protein inhibited host cell transcription, RNA processing and modification, protein synthesis, posttranscriptional modification and transport; and this type of inhibition may very well be weakened when most of M protein was confined exterior the nucleus.
Extra importantly, we discovered that the operate of M protein within the cytoplasm effected the inhibition of TIFA expression in a dose-dependent method, and promoted NDV replication by down-regulating TIFA/TRAF6/NF-κB-mediated manufacturing of cytokines. It was the primary report in regards to the involvement of M protein in NDV immune evasion.
Taken collectively, our findings show that NDV replication is intently associated to the nucleocytoplasmic trafficking of M protein, which accelerates our understanding of the molecular features of NDV M protein.
Hepatic Transporter Alterations by Nuclear Receptor Agonist T0901317 in Sandwich-cultured Human Hepatocytes: Proteomic Evaluation and PBPK Modeling to Consider Drug-Drug Interplay Danger.
In vitro approaches for predicting drug-drug interactions (DDIs) attributable to alterations in transporter protein regulation usually are not properly established. Nonetheless, studies of transporter regulation through nuclear receptor (NR) modulation by medicine are growing. This research examined alterations in transporter protein ranges in sandwich-cultured human hepatocytes (SCHH; n = three donors) measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic evaluation after therapy with T0901317, the primary described artificial liver X receptor (LXR) agonist.
T0901317 therapy (10 μM, 48 h) decreased the degrees of natural cation transporter (OCT) 1 (0.22-, 0.43- and 0.71-fold of management) and natural anion transporter (OAT) 2 (0.38-, 0.38- and 0.53-fold of management), and elevated multidrug resistance protein (MDR) 1 (1.37-, 1.48 and 1.59-fold of management).
The induction of NR downstream gene expression help the speculation that T0901317 off-target results on farnesoid X receptor (FXR) and pregnane X receptor (PXR) activation are liable for the sudden modifications in OCT1, OAT2 and MDR1. Uptake of the OCT1 substrate metformin in SCHH was decreased by T0901317 therapy.
Results of decreased OCT1 ranges on metformin had been simulated utilizing a physiologically-based pharmacokinetic (PBPK) mannequin. Simulations confirmed a transparent lower in metformin hepatic publicity leading to a decreased pharmacodynamic impact.
This DDI wouldn’t be predicted by the modest modifications in simulated metformin plasma concentrations. Altogether, the present research demonstrated that an strategy combining SCHH, proteomic evaluation, and PBPK modeling is helpful for revealing tissue concentration-based DDIs on account of sudden regulation of hepatic transporters by NR modulators.
SIGNIFICANCE STATEMENT: This research utilized an strategy combining sandwich-cultured human hepatocytes, proteomic evaluation, and physiologically-based pharmacokinetic modeling to guage alterations in pharmacokinetics (PK) and pharmacodynamics (PD) on account of transporter regulation by nuclear receptor modulators.
Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594) |
43R-ID012AF |
Fitzgerald |
300 ug |
EUR 492 |
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594) |
Donkey Anti-Goat IgG (H+L), Alexa Fluor® 594 Conjugated |
Ab8011-001 |
GenDepot |
1mg |
EUR 400.8 |
XFD594 tyramide reagent *Same Structure to Alexa Fluor™ 594 tyramide* |
11082 |
AAT Bioquest |
200 slides |
EUR 222 |
Endoglin/CD105 Alexa Fluor |
FC15024 |
Neuromics |
100 Tests |
EUR 537.6 |
Concanavalin A, XFD594 Labeled *XFD594 Same Structure to Alexa Fluor™ 594* |
25575 |
AAT Bioquest |
1 mg |
EUR 102 |
XFD594 NHS Ester *Same Structure to Alexa Fluor™ 594 NHS Ester* |
71908 |
AAT Bioquest |
5 mg |
EUR 781 |
Wheat Germ Agglutinin, XFD594 Labeled *XFD594 Same Structure to Alexa Fluor™ 594* |
25509 |
AAT Bioquest |
1 mg |
EUR 102 |
EGFR antibody (Alexa Fluor 488) |
61R-E109BAF |
Fitzgerald |
125 ug |
EUR 847.2 |
Description: Mouse monoclonal EGFR antibody (Alexa Fluor 488) |
SAM FCM (Alexa Fluor 647) |
abx098902-100tests |
Abbexa |
100 tests |
EUR 1479.6 |
|
SAM FCM (Alexa Fluor 488) |
abx098904-60tests |
Abbexa |
60 tests |
EUR 1629.6 |
|
Alpha Fluor™ 594 C5 Maleimide |
1891 |
AAT Bioquest |
1 mg |
EUR 262.8 |
|
Streptavidin-Alexa594 (Alexas fluor 594) conjugate |
SV-A594-100 |
Alpha Diagnostics |
100 tests |
EUR 270 |
Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG) |
50337 |
Alpha Diagnostics |
0.5 ml |
EUR 270 |
XFD594 Anti-human CD47 Antibody *HI172, XFD594 Same Structure to Alexa Fluor™ 594* |
10471170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD47 Antibody *HI172, XFD594 Same Structure to Alexa Fluor™ 594* |
10471171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD52 Antibody *HI186, XFD594 Same Structure to Alexa Fluor™ 594* |
10520170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD52 Antibody *HI186, XFD594 Same Structure to Alexa Fluor™ 594* |
10520171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD53 Antibody *HI29, XFD594 Same Structure to Alexa Fluor™ 594* |
10530170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD53 Antibody *HI29, XFD594 Same Structure to Alexa Fluor™ 594* |
10530171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD53 Antibody *HI36, XFD594 Same Structure to Alexa Fluor™ 594* |
10531170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD53 Antibody *HI36, XFD594 Same Structure to Alexa Fluor™ 594* |
10531171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD55 Antibody *HI55a, XFD594 Same Structure to Alexa Fluor™ 594* |
10550170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD55 Antibody *HI55a, XFD594 Same Structure to Alexa Fluor™ 594* |
10550171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD56 Antibody *My31, XFD594 Same Structure to Alexa Fluor™ 594* |
10562160 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD56 Antibody *My31, XFD594 Same Structure to Alexa Fluor™ 594* |
10562161 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD57 Antibody *HI57a, XFD594 Same Structure to Alexa Fluor™ 594* |
10570170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD57 Antibody *HI57a, XFD594 Same Structure to Alexa Fluor™ 594* |
10570171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD58 Antibody *HI58a, XFD594 Same Structure to Alexa Fluor™ 594* |
10580170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD58 Antibody *HI58a, XFD594 Same Structure to Alexa Fluor™ 594* |
10580171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD62 Antibody *HI62E, XFD594 Same Structure to Alexa Fluor™ 594* |
10620170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD62 Antibody *HI62E, XFD594 Same Structure to Alexa Fluor™ 594* |
10620171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD62l Antibody *HI62L, XFD594 Same Structure to Alexa Fluor™ 594* |
10621170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD62l Antibody *HI62L, XFD594 Same Structure to Alexa Fluor™ 594* |
10621171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD62p Antibody *HI62P, XFD594 Same Structure to Alexa Fluor™ 594* |
10622170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD62p Antibody *HI62P, XFD594 Same Structure to Alexa Fluor™ 594* |
10622171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD64 Antibody *10.1, XFD594 Same Structure to Alexa Fluor™ 594* |
10640170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD64 Antibody *10.1, XFD594 Same Structure to Alexa Fluor™ 594* |
10640171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD69 Antibody *FN50, XFD594 Same Structure to Alexa Fluor™ 594* |
10690170 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-human CD69 Antibody *FN50, XFD594 Same Structure to Alexa Fluor™ 594* |
10690171 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD71 Antibody *HI160, XFD594 Same Structure to Alexa Fluor™ 594* |
10710170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD71 Antibody *HI160, XFD594 Same Structure to Alexa Fluor™ 594* |
10710171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD71 Antibody *HI166, XFD594 Same Structure to Alexa Fluor™ 594* |
10711170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD71 Antibody *HI166, XFD594 Same Structure to Alexa Fluor™ 594* |
10711171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD72 Antibody *3F3, XFD594 Same Structure to Alexa Fluor™ 594* |
10720170 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-human CD72 Antibody *3F3, XFD594 Same Structure to Alexa Fluor™ 594* |
10720171 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD73 Antibody *AD2, XFD594 Same Structure to Alexa Fluor™ 594* |
10730170 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-human CD73 Antibody *AD2, XFD594 Same Structure to Alexa Fluor™ 594* |
10730171 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD5 Antibody *HISM2, XFD594 Same Structure to Alexa Fluor™ 594* |
10050170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD5 Antibody *HISM2, XFD594 Same Structure to Alexa Fluor™ 594* |
10050171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD5 Antibody *L17F12, XFD594 Same Structure to Alexa Fluor™ 594* |
10051170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD5 Antibody *L17F12, XFD594 Same Structure to Alexa Fluor™ 594* |
10051171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD5 Antibody *UCHT2, XFD594 Same Structure to Alexa Fluor™ 594* |
10052170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD5 Antibody *UCHT2, XFD594 Same Structure to Alexa Fluor™ 594* |
10052171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD6 Antibody *HI210, XFD594 Same Structure to Alexa Fluor™ 594* |
10060170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD6 Antibody *HI210, XFD594 Same Structure to Alexa Fluor™ 594* |
10060171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD7 Antibody *HIT7, XFD594 Same Structure to Alexa Fluor™ 594* |
10070170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD7 Antibody *HIT7, XFD594 Same Structure to Alexa Fluor™ 594* |
10070171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD8 Antibody *HIT8a, XFD594 Same Structure to Alexa Fluor™ 594* |
10080170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD8 Antibody *HIT8a, XFD594 Same Structure to Alexa Fluor™ 594* |
10080171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD8 Antibody *SK1, XFD594 Same Structure to Alexa Fluor™ 594* |
10081170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD8 Antibody *SK1, XFD594 Same Structure to Alexa Fluor™ 594* |
10081171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD9 Antibody *HI9a, XFD594 Same Structure to Alexa Fluor™ 594* |
10090170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD9 Antibody *HI9a, XFD594 Same Structure to Alexa Fluor™ 594* |
10090171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD10 Antibody *HI10a, XFD594 Same Structure to Alexa Fluor™ 594* |
10100170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD10 Antibody *HI10a, XFD594 Same Structure to Alexa Fluor™ 594* |
10100171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD11a Antibody *HI111, XFD594 Same Structure to Alexa Fluor™ 594* |
10110170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD11a Antibody *HI111, XFD594 Same Structure to Alexa Fluor™ 594* |
10110171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD11b Antibody *HI11b, XFD594 Same Structure to Alexa Fluor™ 594* |
10111170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD11b Antibody *HI11b, XFD594 Same Structure to Alexa Fluor™ 594* |
10111171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD11b Antibody *ICRF44, XFD594 Same Structure to Alexa Fluor™ 594* |
10112170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD11b Antibody *ICRF44, XFD594 Same Structure to Alexa Fluor™ 594* |
10112171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD11c Antibody *3.9, XFD594 Same Structure to Alexa Fluor™ 594* |
10113170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD11c Antibody *3.9, XFD594 Same Structure to Alexa Fluor™ 594* |
10113171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD13 Antibody *WM15, XFD594 Same Structure to Alexa Fluor™ 594* |
10130170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD13 Antibody *WM15, XFD594 Same Structure to Alexa Fluor™ 594* |
10130171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD14 Antibody *61D3, XFD594 Same Structure to Alexa Fluor™ 594* |
10141170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD14 Antibody *61D3, XFD594 Same Structure to Alexa Fluor™ 594* |
10141171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD15 Antibody *HI98, XFD594 Same Structure to Alexa Fluor™ 594* |
10150170 |
AAT Bioquest |
100 tests |
EUR 296 |
XFD594 Anti-human CD15 Antibody *HI98, XFD594 Same Structure to Alexa Fluor™ 594* |
10150171 |
AAT Bioquest |
500 tests |
EUR 1020 |
XFD594 Anti-human CD16 Antibody *HI16a, XFD594 Same Structure to Alexa Fluor™ 594* |
10160170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD16 Antibody *HI16a, XFD594 Same Structure to Alexa Fluor™ 594* |
10160171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD16 Antibody *3G8, XFD594 Same Structure to Alexa Fluor™ 594* |
10161170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD16 Antibody *3G8, XFD594 Same Structure to Alexa Fluor™ 594* |
10161171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD18 Antibody *HI18a, XFD594 Same Structure to Alexa Fluor™ 594* |
10180170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD18 Antibody *HI18a, XFD594 Same Structure to Alexa Fluor™ 594* |
10180171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD19 Antibody *HI19a, XFD594 Same Structure to Alexa Fluor™ 594* |
10190170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD19 Antibody *HI19a, XFD594 Same Structure to Alexa Fluor™ 594* |
10190171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD19 Antibody *SJ25C1, XFD594 Same Structure to Alexa Fluor™ 594* |
10191170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD19 Antibody *SJ25C1, XFD594 Same Structure to Alexa Fluor™ 594* |
10191171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD19 Antibody *HIB19, XFD594 Same Structure to Alexa Fluor™ 594* |
10192170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD19 Antibody *HIB19, XFD594 Same Structure to Alexa Fluor™ 594* |
10192171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD19 Antibody *4G7, XFD594 Same Structure to Alexa Fluor™ 594* |
10193170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD19 Antibody *4G7, XFD594 Same Structure to Alexa Fluor™ 594* |
10193171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-mouse CD19 Antibody *1D3, XFD594 Same Structure to Alexa Fluor™ 594* |
10194160 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-mouse CD19 Antibody *1D3, XFD594 Same Structure to Alexa Fluor™ 594* |
10194161 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD20 Antibody *HI20a, XFD594 Same Structure to Alexa Fluor™ 594* |
10201170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD20 Antibody *HI20a, XFD594 Same Structure to Alexa Fluor™ 594* |
10201171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD21 Antibody *HI21a, XFD594 Same Structure to Alexa Fluor™ 594* |
10210170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD21 Antibody *HI21a, XFD594 Same Structure to Alexa Fluor™ 594* |
10210171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD22 Antibody *HIB22, XFD594 Same Structure to Alexa Fluor™ 594* |
10220170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD22 Antibody *HIB22, XFD594 Same Structure to Alexa Fluor™ 594* |
10220171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD101 Antibody *BB27, XFD594 Same Structure to Alexa Fluor™ 594* |
11010160 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-human CD101 Antibody *BB27, XFD594 Same Structure to Alexa Fluor™ 594* |
11010161 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD107 Antibody *H4B4, XFD594 Same Structure to Alexa Fluor™ 594* |
11071160 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-human CD107 Antibody *H4B4, XFD594 Same Structure to Alexa Fluor™ 594* |
11071161 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD109 Antibody *W7C5, XFD594 Same Structure to Alexa Fluor™ 594* |
11090160 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-human CD109 Antibody *W7C5, XFD594 Same Structure to Alexa Fluor™ 594* |
11090161 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD111 Antibody *R1.302, XFD594 Same Structure to Alexa Fluor™ 594* |
11110160 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-human CD111 Antibody *R1.302, XFD594 Same Structure to Alexa Fluor™ 594* |
11110161 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD112 Antibody *R2.525, XFD594 Same Structure to Alexa Fluor™ 594* |
11120160 |
AAT Bioquest |
100 tests |
EUR 547 |
The significance of this strategy from a mechanistic and clinically-relevant perspective is that it could actually reveal drug-drug interactions (DDIs) on account of sudden regulation of hepatic transporters, and allow prediction of altered PK and PD modifications, particularly for tissue concentration-based DDIs.